37. 膿疱性乾癬(汎発型) Generalised pustular psoriasis Clinical trials / Disease details


臨床試験数 : 74 薬物数 : 53 - (DrugBank : 20) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 101

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03998683
(ClinicalTrials.gov)
September 3, 201925/6/2019A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisPsoriasisDrug: Guselkumab 100 mg;Drug: PlaceboJanssen-Cilag Ltd.NULLCompleted18 YearsN/AAll117Phase 3France;Germany;Italy;Spain;United Kingdom
2EUCTR2018-003206-58-GB
(EUCTR)
29/07/201928/05/2019A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: TREMFYA®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB
Janssen-Cilag International N.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
105Phase 3France;Spain;Germany;United Kingdom
3EUCTR2018-003206-58-IT
(EUCTR)
11/07/201915/06/2021A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: TREMFYA
Product Name: GUSELKUMAB
Product Code: [CNTO1959]
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB
JANSSEN CILAG INTERNATIONAL NVNULLNot RecruitingFemale: yes
Male: yes
105Phase 3France;Spain;Germany;United Kingdom;Italy
4EUCTR2018-003206-58-DE
(EUCTR)
02/07/201925/04/2019A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: TREMFYA®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
105Phase 3France;Spain;Germany;Italy;United Kingdom
5EUCTR2018-003206-58-FR
(EUCTR)
29/06/201911/04/2019A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: TREMFYA®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB
Janssen-Cilag International N.V.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
105 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;Spain;Germany;United Kingdom
6EUCTR2018-003206-58-ES
(EUCTR)
20/06/201908/05/2019A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: TREMFYA®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB
Janssen-Cilag International N.V.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
105 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;Spain;Germany;United Kingdom
7NCT02343744
(ClinicalTrials.gov)
January 19, 201516/1/2015An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisA Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPustular PsoriasisDrug: GuselkumabJanssen Pharmaceutical K.K.NULLCompleted20 YearsN/AAll21Phase 3Japan